Phase 2 study of Pemetrexed + Carboplatin as first line therapy for non-squamous non-small cell lung cancer without EGFR Mutation (CJLSG0906).
Phase of Trial: Phase II
Latest Information Update: 13 May 2016
At a glance
- Drugs Pemetrexed (Primary) ; Carboplatin
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 01 Apr 2016 Results published in the Anticancer Research
- 30 Mar 2012 Status changed from recruiting to active, no longer recruiting as reported by University Hospital Medical Information Network - Japan record.
- 09 Nov 2011 New trial record